Research Article
[Retracted] Significance of the Expression of TC and TG Levels in the Initial Diagnosis and Treatment of SCLC Patients and Their Tie-In with Prognosis
Table 2
Univariate analysis of clinical data differences in the prognosis of SCLC patients with progression-free survival time.
| Index | PFS (months) | t | P |
| Gender | Male (n = 62) | 9.85 ± 1.23 | −0.957 | 0.341 | | Female (n = 28) | 10.12 ± 1.26 | Age | >65 years old (n = 31) | 9.89 ± 1.32 | −0.236 | 0.814 | | ≤65 years old (n = 59) | 9.96 ± 1.35 | Tumor stage | Limited period (n = 51) | 12.59 ± 1.63 | 16.607 | <0.001 | | Extensive period (n = 39) | 7.33 ± 1.28 | Distant metastasis | Yes (n = 21) | 10.59 ± 1.57 | −1.654 | 0.102 | | No (n = 69) | 11.19 ± 1.42 | Lymph node metastasis | Yes (n = 25) | 8.99 ± 1.26 | −1.847 | 0.068 | | No (n = 65) | 9.56 ± 1.33 | BIM classification | <18.5 kg/m2 (n = 20) | 6.73 ± 1.02 | −1.632 | 0.106 | | 18.5∼24.9 kg/m2 (n = 33) | 10.69 ± 1.42 | | >24.9 kg/m2 (n = 37) | 8.23 ± 1.34 | Smoking status | Yes (n = 62) | 9.55 ± 1.36 | −1.157 | 0.250 | | No (n = 28) | 9.91 ± 1.38 | HDL-C | <1.0 mmol/l (n = 42) | 9.89 ± 1.42 | 1.286 | 0.202 | | ≥1.0 mmol/l (n = 48) | 9.51 ± 1.38 | TC | >5.5 mmol/L (n = 47) | 7.52 ± 1.15 | −16.545 | <0.001 | | ≤5.5 mmol/l (n = 43) | 12.33 ± 1.59 | TG | >1.7 mmol/L (n = 39) | 12.95 ± 1.69 | 23.209 | <0.001 | | ≤1.7 mmol/l (n = 51) | 6.13 ± 1.09 | Operation | Yes (n = 62) | 10.15 ± 1.48 | 1.441 | 0.153 | | No (n = 28) | 9.68 ± 1.32 | Radiotherapy | Yes (n = 65) | 10.25 ± 1.52 | 1.939 | 0.056 | | No (n = 25) | 9.56 ± 1.49 |
|
|